Group items tagged

The Health and Social Care Committee (HSCC) has announced the appointment of six specialists to scrutinise the government's progress made on its commitments to pharmacy services in England on Wednesday (26 April). "They will work alongside the core members of the Expert Panel to produce a report evaluating Government progress across nine of the Government's own commitments across the four areas. A CQC-style rating from "inadequate" to "outstanding" will be awarded against each specific pledge with a final overall rating given," said DHSC. Professor Dame Jane Dacre, Chair of the Expert Panel, said: "The role of pharmacy in delivering care whether in hospital, the community or primary care has never been more important. "The Government has made a number of commitments aimed at improving pharmacy services and we'll be looking at the progress to achieve these targets. "In the process of our evaluation we'll be hearing from stakeholders from across the industry, including the pharmacy workforce and NHS and independent providers of pharmacy services. We'll be considering pledges covering frontline services as well as the education and training of the workforce." National Pharmacy Association (NPA) chief executive, Mark Lyonette, is one of six panel members with specialist expertise in pharmacy. They will work alongside five standing members who are all renowned healthcare policy experts and professionals. Professor Dame Jane Dacre will chair.

Researchers at at an Australian university have developed a new form of antibiotic that can be swiftly re-engineered to avoid resistance to dangerous superbugs. The antibiotic, which was developed by PhD candidate Priscila Cardoso and major supervisor Dr Celine Valery from RMIT's School of Health and Biosciences, has a basic architecture that allows it to be generated quickly and cheaply in a lab. The antibiotic, Priscilicidin, has tiny amino acid building blocks that allow it to be tailored to combat various types of antimicrobial resistance. With the World Health Organization calling antimicrobial resistance "one of the top ten global public health threats facing humanity", developing new antibiotics has become more urgent than ever. Professor Charlotte Conn, one of Cardoso's PhD supervisors, said given that urgency, Priscilicidin was an exciting breakthrough for public health. Priscilicidin is a type of antimicrobial peptide. These peptides are produced by all living organisms as the first defence against bacteria and viruses.

Dry eye syndrome is incredibly common and prevalence is increasing globally. Studies show that prevalence rates vary from five to 50 per cent but can be as high as 75 per cent in people over the age of 40, in people who wear contact lenses and those who work with computers. It is more common in women than in men, particularly during and after the menopause. According to a new real-world research commissioned by world experts in eye-care, Rohto, more than eight in ten women (83 per cent) indicate that they suffer from the condition, but only once they have had the symptoms of dry eye syndrome described to them. Without detailed explanation, 56 per cent of people say they have never even heard of dry eye syndrome, showing just how under diagnosed it may be. Causes of dry eye Dry eyes are a clinical cause of eye irritation, fatigue, and discomfort, often causing feelings of itchiness, grittiness, and excess watering. If left untreated, dry eyes can even lead to long-term damage and sight problems. Dry eyes may occur if enough tears aren't produced if poor-quality tears are generated or if the tears evaporate from the surface of the eye too quickly. This leads to poor lubrication of the tear film. In a normal eye, the tear film4- the multilayer moist protective film - covers the cornea and lubricates the eye. However, if the lubricative process is faulty dry spots appear on the surface of the eye and this causes irritation and discomfort. The tear film has several layers: fatty oils, aqueous fluid, and mucus. This combination normally keeps the surface of your eyes lubricated, smooth and clear. But problems with any of these layers can cause dry eyes.

Health authorities in India have said that Biological E's Covid-19 vaccine Corbevax can be administered as a booster dose in people who have taken the country's other two main shots, Covaxin and AstraZeneca's Covishield, from Friday (Aug 12). Corbevax will be available to over 18s as precautionary booster six months after a second dose, the health ministry said in an August 8 letter to state authorities. Covishield is produced for the Indian market by the Serum Institute of India under licence from AstraZeneca, while Bharat Biotech makes Covaxin. India has so far administered more than 2 billion Covid vaccine shots, including 113 million boosters, all of which have so far been of the same vaccine as the recipient's first two doses. The government says about 89 per cent of Indians above the age of 12 have had two doses.

The Royal Pharmaceutical Society (RPS) has confirmed it will respond to UK Commission's 'call for evidence' on pharmacy professional leadership. The commission wants to ensure the professions are well equipped, with a voice to help shape the future, and enabled to develop through sharing and learning from best practice. The UK Commission on Pharmacy Professional Leadership has been set up by the chief pharmaceutical officers of England, Scotland, Wales and Northern Ireland. It will produce recommendations for the future of pharmacy professional leadership in the UK. The commission is co-chaired by Nigel Clarke, former chair of the General Pharmaceutical Council, and Professor Dame Jane Dacre, professor of medical education at University College London's Medical School. The commission will be hosting a webinar and has urged the associations and individuals to take part in 'call for evidence' which has been launched to inform and develop its work. A webinar in England will take place on Wednesday 7 September 6:30 - 8 pm. In Scotland it will be organised on Tuesday 6 September 7-8:30 pm and in Wales it will be hosted on Thursday 8 September 7-8:30 pm.

The Pharmacists' Defence Association (PDA) has urged pharmacists working in Covid-19 vaccination role to report any concerns about the needles and syringes supplied with the Moderna Spikevax Bivalent vaccine. The association has heard reports of bending when vaccinators pierce the top of the vial containing the Covid-19 vaccine doses, needles falling out during manipulation and appearing to be bent even before removal from the packaging. PDA has advised its members who are working in a Covid-19 vaccination role "to report any concerns via the Yellow Card medical device reporting system, and to keep up to date with NHS clinical updates for ongoing information and guidance." Current advice from the NHS includes sharing of video and poster resources (available on FutureNHS) which have been produced by the supplier to support the introduction of the new administration needles and syringes for Spikevax Bivalent. This is following a switch from BD Flu+ 23G x 25mm 1ml syringe combined needle and syringe (CNS) to the Owen Mumford Unifine Safety Retractable Needle 25G x 25mm & 1ml Syringe.

The UK must act swiftly to fend off competition if it wants to build the world's leading life sciences sciences hub, a new report suggests. A year on from the launch of the government's life science vision, the report commissioned by the the Association of the British Pharmaceutical Industry said although achieving the ambition remained feasible, the UK would need an attractive business environment because its competitor countries were becoming more adept at attracting investment. To achieve the ambition of the vision, the PwC-produced report suggested raising pharmaceutical R&D investment in the UK to build a 'stronger manufacturing and research infrastructure', alongside better investment in, access to and uptake of innovative medicines. It said the UK would also need to adopt a renewed approach to the priority healthcare challenges identified in the government's 'Life Science Vision', which would mean cutting the overall burden on health of dementia, cancer, cardiovascular and respiratory disease and mental health. The report quantified the size of the prize if the vision was implemented in full and the UK could emulate the successes of leading EU countries, which included: £68 billion in additional GDP over 30 years, owing to increased R&D investment £16.3 billion additional annual GDP from increased pharmaceutical exports Supporting 85,000 additional jobs Up to 40 per cent decrease in disease burden across the whole UK - for areas like cardiovascular disease, mental health conditions and Cancer. Reduced variation in speed of access to new medicines within three months of licensing for all NHS patients.

The pharmaceutical industry is one of the most important and valuable industries in the world. It is responsible for developing and producing medicines that improve and save lives. However, there are some things you may not know about this fascinating industry. In this blog post, we will discuss six interesting facts about the pharmaceutical industry! 1. THE MANUFACTURING PROCESS OF PHARMACEUTICALS IS HIGHLY REGULATED All pharmaceutical products must go through a rigorous manufacturing process before they can be made available to patients. This process is heavily regulated by various government agencies to ensure that the medicines are safe and effective. The pharmaceutical manufacturing process usually involves multiple steps, including the preparation of raw materials, the manufacturing of active pharmaceutical ingredients (APIs), and the packaging and labeling of finished products. To ensure patient safety, all pharmaceutical companies must adhere to strict regulations set by government agencies such as the Food and Drug Administration (FDA). These regulations are designed to protect patients by ensuring that medicines are safe and effective.

In a long scripted overhaul of its business, GlaxoSmithKline spun off its consumer health business on Monday (July 18) in the biggest listing in Europe for more than a decade. The new company, Haleon, becomes the world's biggest standalone consumer health business, home to brands including Sensodyne toothpaste, pain relief drug Panadol and cold treatment Theraflu. Shares in Haleon started trading at 330 pence on Monday morning, giving the business a market valuation of around £30.5 billion - dashing high hopes for Haleon's much higher market valuation after GSK in January said it had rebuffed a £50 billion offer from Unilever on the basis it was too low. The major strategy shift by GSK chief executive Emma Walmsley to focus on the company's core pharmaceuticals business comes after she faced intense activist shareholder pressure over its delays in producing Covid jabs and treatments.

Pharmacists, politicians, faith and community leaders paid tribute to Parvatiben Solanki, the co-founder of the Asian Media Group (AMG), publishers of Pharmacy Business magazine. Mrs Solanki passed away in London last Thursday (September 8). She was 86. Along with her husband, the late Ramniklal Solanki CBE, Mrs Solanki played a key role in establishing AMG as one of Britain's largest Asian publishing houses. They began the business in April 1968, producing the flagship title, Garavi Gujarat, from their terraced house in Wembley, north London. Today AMG publishes a range of trade and consumer titles, including Pharmacy Business, Asian Trader, Garavi Gujarat and Eastern Eye, in addition to hosting gala awards dinners. AMG has offices in the UK, US and India, and also publishes titles in the United States.

Technological innovation has touched our lives in immeasurable ways, from city infrastructure to personal entertainment and beyond. Even our health and conditions have been improved by the right tech innovations; contact lenses were one such innovation, having been safely pioneered as recently as the 19th century. But there are more recent developments which could change the lives of contact lens users forever; what are they? Smart Touch Contact Lenses While Smart Touch lenses are a relatively simple innovation, it is often the simple innovations that have the most fundamental impact on contact lens users. Smart Touch lenses are a new type of contact lens produced with a breathable material to promote eye health throughout the day. The key innovation lies in the packaging; Smart Touch contact lenses are provided in a bespoke blister packaging solution that delivers the lenses face-up. This ensures that the user never needs to touch the inner surface of the lens, keeping it hygienic and allowing for quick, unobtrusive application. These contact lenses provide innovative solutions for lens-wearers, and represent the power of slight technological improvements to existing products.

At the Conservative Party Conference, PM Rishi Sunak pledged to raise the legal age every year to buy from those who were born in 2009. The proposed changes also encompass heated tobacco products, recognized as smoke-free alternatives that heat, not burn, tobacco to produce a distinct nicotine-containing aerosol compared to traditional cigarette smoke. The following move in a bid to "try and stop teenagers taking up cigarettes in the first place", and bring in restrictions to stop young people from vaping. PM Rishi Sunak spoke at the conference, "Last week I promised to create the first smoke-free generation and I am wasting no time to deliver on that promise.

Dr Michael Gamlen, the inventor of Gamlen instruments presents a tablet press machine to the students at the School of Pharmacy on 16 October. The equipment not only solves the challenge of producing lab-scale tablets under precise conditions but also offers valuable insights into material compaction properties. It is also known as a powder compaction analyser which has been given on loan to the University of Sunderland for five years. Dr Gamlen talks about the machine and how pharmacy students will benefit, saying: "It allows you to make tablets under tightly controlled conditions and enables you to make accurate comparisons between different materials and processes. "The students will be able to easily see the impact of the tablet compaction conditions on tablet properties. This is very important to understand when developing new tablet formulations and manufacturing products."

The Scottish government is planning to publish its review report on use of automated technology in community pharmacies by the end of 2023. The technology being trialled as part of the pilot includes robotic process automation, automated medicine storage systems, barcode scanners and prescription collection kiosks. The evaluation, which started prior to the COVID-19 pandemic, is due to be completed at the end of November 2023. Patricia Findlay, professor of work and employment relations at the University of Strathclyde, who was commissioned to produce the report, told The Pharmaceutical Journal that the pilot pharmacies taking part in the scheme are all based in Scotland, but she didn't reveal their names.

The National Institute for Health and Care Excellence (NICE) has recommended pembrolizumab in combination with chemotherapy (paclitaxel or nab-paclitaxel) which is said to benefit people with triple negative breast cancer. Clinical trial evidence shows that, compared with paclitaxel, pembrolizumab combination increases how long people have before their cancer gets worse and how long they live. NICE already recommends atezolizumab in combination with chemotherapy for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer. Atezolizumab combination is recommended by NICE for people with IC equal to or greater than 1%. "This means that some people who can't have atezolizumab combination could be eligible for pembrolizumab combination," said NICE. NICE's independent appraisal committee also agreed that the pembrolizumab combination meets the higher cost-effectiveness threshold for life-extending treatments for people with a short life expectancy. Given by injection every 3 weeks, pembrolizumab (also called Keytruda and made by Merck Sharp and Dohme) is a type of immunotherapy that specifically targets triple negative breast cancer. It works by blocking the activity of a protein known as PD-L1 which is produced in larger amounts on cancerous cells than normal cells. By blocking PD-L1 it helps the person's own immune cells to attack the cancer.

Acknowledging publication of the Royal Pharmaceutical Society (RPS) Scotland's new professional vision for the future of pharmacy in Scotland - Pharmacy 2030, a Parliamentary Motion has been lodged in the Scottish Parliament. The vision, produced in collaboration with the National Pharmacy Technician Group Scotland, expects all pharmacists in a patient-facing role to become independent prescribers by 2030. The motion recognised the aim of the publication that by 2030 pharmacy teams will work together, using their expertise to make the best use of medicines and, will take a person-centred approach, providing care holistically rather than by clinical condition. It highlighted the important role that RPS would play by working with partners across health and social care to turn this vision into a reality.

Thirty-five generic drug manufacturers will make a more affordable version of Pfizer's anti-Covid pill for the world's poorer nations, in licensing deals announced Thursday (17) by a UN-backed organisation. The global Medicines Patent Pool (MPP) signed agreements with three dozen manufacturers to produce the oral Covid-19 treatment nirmatrelvir for supply in 95 low- and middle-income countries. US pharmaceutical giant Pfizer signed a licence agreement with the MPP in November. The MPP, in turn, issued sub-licences to the generic drugs makers. The deals announced Thursday will "help ensure access to our oral Covid-19 treatment for patients in need around the world", said Pfizer chairman Albert Bourla.

Following concerns raised about cracked cartridges and insulin leaks, the Medicines and Healthcare products Regulatory Agency (MHRA) has issued a national patient safety alert for the NovoRapid PumpCart prefilled insulin cartridge and the Roche Accu-Chek Insight Insulin pump system. The regulator have asked patients to check the pre-filled glass insulin cartridge for cracks before use. It advised against using the cartridge if it has been dropped even if no cracks are visible and urged to closely follow the updated handling instructions in the pump user manual when changing pre-filled glass insulin cartridges. In some of the reported leakage incidents, the cartridges were found to be cracked and provided an inadequate supply of insulin to patients. Leakages also occurred in cases where no cracks in the cartridge were visible, the regulator said. In some patients there were consequences of not receiving enough insulin from their pump system, including reports of severely high blood sugar and diabetic ketoacidosis, a serious complication of diabetes when the body produces high levels of blood acids called ketones. Healthcare professionals are being advised to contact patients over the next six months using said device to discuss their individual needs and source an alternative pump where appropriate. "Because of the rare risk of insulin leakage from the Roche Accu-Chek Insight Insulin Pump, patients should check the pre-filled glass insulin cartridge for any cracks prior to usage," Dr June Raine, MHRA chief executive, said.

The National Institute for Health and Care Excellence (NICE) has recommended abemaciclib also called Verzenios, made by Eli Lilly, for people with hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence who have had surgery to remove their tumour. The clinical trial result showed that people having abemaciclib with hormone therapy had a more than 30 per cent better chance of their cancer not coming back following surgery compared with people having hormone therapy alone. Helen Knight, interim director of medicines evaluation at NICE, said: "Today's positive draft recommendation, which comes less than a month after abemaciclib received its licence, is fantastic news. The fact that we have been able to produce draft recommendations so quickly is testament to the success of our ambition to support patient access to clinically and cost effective treatments as early as possible. "Until now there have been no targeted treatments for people with this type of breast cancer. Abemaciclib with hormone therapy represents a significant improvement in how it is treated because being able to have a targeted treatment earlier after surgery will increase the chance of curing the disease and reduce the likelihood of developing incurable advanced disease."

US biotech firm Moderna will build a new research and manufacturing centre in Britain to develop vaccines against new Covid-19 variants, other respiratory illnesses and help improve readiness for any future pandemics. The facility is expected to start producing shots in 2025 and Britain has made a commitment to buy Moderna's vaccines for the next decade under the agreement. Moderna's Covid-19 vaccines, which use messenger RNA (mRNA) technology, were among those deployed in Britain to tackle the crisis and enable prime minister Boris Johnson to reopen the economy from stringent lockdowns. Moderna chief executive Stephane Bancel said the priority was to develop a shot combining refreshed boosters against Covid, flu and Respiratory Syncytial Virus (RSV). "By building a plant in the UK, we are also providing the UK Government - which has a long term partnership with us, with this agreement - with the ability to be pandemic ready," Bancel said on Wednesday.